In a clinical trial for Transthyretin amyloidosis gene therapy [NCT04601051], lipid nanoparticles have efficiently been used for in vivo delivery of a CRISPR-Cas9 system resulting in transthyretin (TTR) protein disruption [216]. Here, TTR is linked to amyloidosis.